Showing results (751-760 of 1,838) with videos related to

Sort By:
Pageof 184
ESMO Open|August 3, 2024
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE studyD Trapani, R Scalia, E Giordano, et al.
ESMO Open|July 23, 2024
Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030S Guzzinati, F Toffolutti, S Francisci, et al.
ESMO Open|July 23, 2024
Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I studyA Algazi, K P Papadopoulos, F Tsai, et al.
ESMO Open|July 13, 2024
Maintenance durvalumab after first-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM studyC Fong, B Patel, C Peckitt, et al.
ESMO Open|August 13, 2024
Addressing the knowledge gap in the genomic landscape and tailored therapeutic approaches to adolescent and young adult cancersN Hayashi, M Ono, I Fukada, et al.
ESMO Open|September 4, 2024
An assessment of the attitudes, knowledge, and education regarding the health care needs of LGBTQ patients with cancer: results of an ESMO/SIOPE global surveyE Saloustros, A Ferrari, I Bozovic-Spasojevic, et al.
ESMO Open|June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumK Takemura, T Yuasa, A Lemelin, et al.
ESMO Open|June 24, 2024
A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumorsM A Gouda, J Shunyakova, A Naing, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
Pageof 184